EA200601747A1 - Три(цикло)замещённые амидные соединения - Google Patents

Три(цикло)замещённые амидные соединения

Info

Publication number
EA200601747A1
EA200601747A1 EA200601747A EA200601747A EA200601747A1 EA 200601747 A1 EA200601747 A1 EA 200601747A1 EA 200601747 A EA200601747 A EA 200601747A EA 200601747 A EA200601747 A EA 200601747A EA 200601747 A1 EA200601747 A1 EA 200601747A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cyclo
substituted
compounds
amida
amida compounds
Prior art date
Application number
EA200601747A
Other languages
English (en)
Other versions
EA012204B1 (ru
Inventor
Мэттью Файф
Original Assignee
Прозидион Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Прозидион Лимитед filed Critical Прозидион Лимитед
Publication of EA200601747A1 publication Critical patent/EA200601747A1/ru
Publication of EA012204B1 publication Critical patent/EA012204B1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/44Acylated amino or imino radicals
    • C07D277/46Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Соединения формулы (I) или их фармацевтически приемлемые соли являются полезными в профилактическом или терапевтическом лечении гипергликемии и диабета.
EA200601747A 2004-04-21 2005-04-19 Три(цикло)замещённые амидные соединения EA012204B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56417104P 2004-04-21 2004-04-21
US60107704P 2004-08-12 2004-08-12
PCT/GB2005/050053 WO2005103021A1 (en) 2004-04-21 2005-04-19 Tri(cyclo) substituted amide compounds

Publications (2)

Publication Number Publication Date
EA200601747A1 true EA200601747A1 (ru) 2007-04-27
EA012204B1 EA012204B1 (ru) 2009-08-28

Family

ID=34965439

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200601747A EA012204B1 (ru) 2004-04-21 2005-04-19 Три(цикло)замещённые амидные соединения

Country Status (15)

Country Link
US (1) US20080242869A1 (ru)
EP (1) EP1740560A1 (ru)
JP (1) JP2007533722A (ru)
KR (1) KR20060134179A (ru)
AU (1) AU2005235798A1 (ru)
BR (1) BRPI0510163A (ru)
CA (1) CA2563192A1 (ru)
EA (1) EA012204B1 (ru)
IL (1) IL178473A0 (ru)
MA (1) MA28545B1 (ru)
MX (1) MXPA06012008A (ru)
NO (1) NO20065260L (ru)
NZ (1) NZ550567A (ru)
WO (1) WO2005103021A1 (ru)
ZA (1) ZA200608489B (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ539013A (en) 2002-10-03 2007-05-31 Novartis Ag Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
JP4700684B2 (ja) 2004-04-02 2011-06-15 ノバルティス アーゲー 2型糖尿病の処置に有用なグルコキナーゼアクティベーターとしてのスルホンアミド−チアゾロピリジン誘導体
CA2561157A1 (en) 2004-04-02 2005-10-13 Novartis Ag Thiazolopyridine derivatives, pharmaceutical conditions containing them and methods of treating glucokinase mediated conditions
BRPI0514147A (pt) * 2004-08-12 2008-05-27 Prosidion Ltd composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos de tratamento profilático ou terapêutico de uma condição onde a ativação de gk é desejável, de tratamento profilático ou terapêutico da hiperglicemia ou diabete e de prevenção da diabete em um ser humano que demosntra hiperglicemia pré-diabética ou toleráncia à glicose prejudicada, e, processo para a preparação do composto
GB0418058D0 (en) * 2004-08-12 2004-09-15 Prosidion Ltd Fluorination process
JP2009509988A (ja) 2005-09-29 2009-03-12 サノフィ−アベンティス フェニル−及びピリジニル−1,2,4−オキサジアゾロン誘導体、その製造方法、及び医薬品としてのその使用
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
US20080293741A1 (en) * 2005-11-03 2008-11-27 Matthew Colin Thor Fyfe Tricyclo Substituted Amides as Glucokinase Modulators
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
US7888504B2 (en) 2006-07-06 2011-02-15 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
US7910747B2 (en) 2006-07-06 2011-03-22 Bristol-Myers Squibb Company Phosphonate and phosphinate pyrazolylamide glucokinase activators
EP2046755A2 (en) 2006-07-24 2009-04-15 F. Hoffmann-Roche AG Pyrazoles as glucokinase activators
US7902248B2 (en) 2006-12-14 2011-03-08 Hoffmann-La Roche Inc. Oxime glucokinase activators
TW200831081A (en) 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
WO2008111473A1 (ja) * 2007-03-07 2008-09-18 Kyorin Pharmaceutical Co., Ltd. グルコキナーゼ活性化物質
PE20091313A1 (es) * 2008-01-15 2009-09-03 Lilly Co Eli (r)-2-(4-ciclopropansulfonil-fenil)-n-pirazin-2-il-3-(tetrahidropiran-4-il)-propionamida cristalina
RU2010134411A (ru) 2008-01-18 2012-02-27 Астеллас Фарма Инк. (Jp) Фенилацетамидное производное
US8258134B2 (en) 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
CA2722733C (en) 2008-04-28 2016-02-23 Kyorin Pharmaceutical Co., Ltd. Cyclopentylacrylamide derivative
NZ589084A (en) 2008-05-16 2012-06-29 Takeda San Diego Inc Glucokinase activators
JP2012510979A (ja) * 2008-12-08 2012-05-17 ユーロスクリーン・ソシエテ・アノニム 化合物、薬学的組成物および代謝障害の治療において使用するための方法
UA104742C2 (ru) 2008-12-19 2014-03-11 Эли Лилли Энд Компани Производные арилциклопропилацетамида, применимые как активаторы глюкокиназы
US8222416B2 (en) 2009-12-14 2012-07-17 Hoffmann-La Roche Inc. Azaindole glucokinase activators
US20130281708A1 (en) 2010-03-18 2013-10-24 Takeda California, Inc. Process for the Production of 2-Amino-5-Fluorothiazole

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610846B1 (en) * 1999-03-29 2003-08-26 Hoffman-La Roche Inc. Heteroaromatic glucokinase activators
KR100455635B1 (ko) * 1999-03-29 2004-11-06 에프. 호프만-라 로슈 아게 글루코키나제 활성화제
US6353111B1 (en) * 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
DE60106599T2 (de) * 2000-05-08 2006-02-09 F. Hoffmann-La Roche Ag Substituierte phenylacetamide und ihre verwendung als glukokinase aktivatoren
JP4138478B2 (ja) * 2000-07-20 2008-08-27 エフ.ホフマン−ラ ロシュ アーゲー アルファ−アシル及びアルファ−ヘテロ原子置換ベンゼンアセトアミドのグルコキナーゼアクチベーター
AU2190202A (en) * 2000-12-06 2002-06-18 Hoffmann La Roche Fused heteroaromatic glucokinase activators
ES2276097T3 (es) * 2002-04-26 2007-06-16 F. Hoffmann-La Roche Ag Fenilacetamidas sustituidas y su empleo0 como activadores de glucoquinasa.
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe

Also Published As

Publication number Publication date
EA012204B1 (ru) 2009-08-28
EP1740560A1 (en) 2007-01-10
JP2007533722A (ja) 2007-11-22
ZA200608489B (en) 2008-06-25
NO20065260L (no) 2006-11-21
CA2563192A1 (en) 2005-11-03
NZ550567A (en) 2010-07-30
IL178473A0 (en) 2007-02-11
AU2005235798A1 (en) 2005-11-03
KR20060134179A (ko) 2006-12-27
MXPA06012008A (es) 2007-01-25
BRPI0510163A (pt) 2007-10-02
US20080242869A1 (en) 2008-10-02
WO2005103021A1 (en) 2005-11-03
MA28545B1 (fr) 2007-04-03

Similar Documents

Publication Publication Date Title
EA200601747A1 (ru) Три(цикло)замещённые амидные соединения
EA200501095A1 (ru) Фенилацетамиды и их применение в качестве модуляторов глюкокиназы
JO2282B1 (en) Oxazole derivatives
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
ATE442142T1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
EA200501849A1 (ru) Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ
NO20085217L (no) Effektive pyrimidinderivater i behandlingen av kreft
NO20070514L (no) Pyrrolotriazin kinase inhibitorer
NO20070782L (no) Tetrapeptidanaloger.
EA200700099A1 (ru) Производные пиридина
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
EA200802050A1 (ru) Новые гетероарилзамещенные ариламинопиридиновые производные в качестве мек ингибиторов
SE0401342D0 (sv) Therapeutic compounds
NO20053042L (no) Anvendelse av spongosin (2-metoksyadenosin) for behandling av smerte, saerlig hyperalgesi.
BRPI0418939A (pt) derivados de nicotinamida e sua utilização como agentes terapêuticos
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
ECSP055844A (es) Nuevos compuestos triciclicos
EA200700407A1 (ru) Производные хиназолина и их использования при лечении тромбоцитемии
EA200601837A1 (ru) Бензоксазины для лечения заболеваний дыхательных путей
CY1109962T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4,5]δεκαν-2-ονης για τη θεραπεια παχυσαρκιας
EA200700901A1 (ru) Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии
EA200700400A1 (ru) Производные n-(1h-индолил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии
MXPA06012143A (es) Arilsulfonamidas y usos relacionados con las mismas.
ATE424821T1 (de) Pyrrolopyridin-2-karbonsäureamide

Legal Events

Date Code Title Description
TK4A Corrections in published eurasian patents
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU